Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23794708.
- Also identified by DOI 10.1158/0008-5472.CAN-13-0687 and PMC identifier 3702635.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2(+) breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.
Medical subject headings
- Breast Neoplasms
- Phosphatidylinositol 3-Kinases
- Erb-b2 Receptor Tyrosine Kinases